Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Linda Neuman, MD
Sunesis Pharmaceuticals
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
124 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- the Canberra Hospital
Garran, Australian Capital Territory, Australia
- Concord Repatriation General Hospital
Concord, New South Wales, Australia
- Haematology Department, Gosford Hospital
Gosford, New South Wales, Australia
- Westmead Hospital
Westmead, New South Wales, Australia
- Royal Brisbane and Women'S Hospital
Brisbane, Queensland, Australia
- Haematology and Bone Marrow Transplant Unit, Royal Adelaide Hospital
Adelaide, South Australia, Australia
- Flinders Medical Centre
Bedford Park, South Australia, Australia
- Andrew Love Cancer Center, Geelong Hospital, Barwon Health
Geelong, Victoria, Australia
- the Alfred Hospital
Melbourne, Victoria, Australia
- Department of Clinical Haematology and Bmt Service, Royal Melbourne Hospital
Parkville, Victoria, Australia
- Royal Perth Hospital
Perth, Western Australia, Australia
- Universitatsklinik Graz, Universitatsklinik Fur Innere Medizin, Abteilung Fur Hamatologie
Graz, Austria
- University Hospital for Internal Medicine V, Innsbruck Medical University
Innsbruck, Austria
- Landeskrankenhaus Salzburg, Universitaetsklinik Fur Innere Medizin Lll, Universitaetsklinikum Der Pmu
Salzburg, Austria
- Akh Wien / Meduniwien Universtatsklinik Fur Innere Medizin 1
Vienna, Austria
- Zna Middleheim Lindendreef 1
Antwerp, Belgium
- Zna Stuivenberg, Lange Beeldekensstraat 267
Antwerp, Belgium
- Az St.-Jan Brugge-Oostende Av
Bruges, Belgium
- Cliniques Universitaires Saint Luc
Brussels, Belgium
- Uz Leuven, Campus Gasthuisberg, Department of Haematology
Leuven, Belgium
- H.-Hartziekenhuis Roeselare - Menen Vzw
Roeselare, Belgium
- Division of Hematology, Vancouver General Hospital
Vancouver, British Columbia, Canada
- Saint John Regional Hospital
Saint John, New Brunswick, Canada
- Queen Elizabeth Ii Health Sciences Centre
Halifax, Nova Scotia, Canada
- University Health Network, Princess Margaret Hospital
Toronto, Ontario, Canada
- Charles Lemoyne Hospital
Greenfield Park, Quebec, Canada
- Fakultni Nemocnice Kralovske Vinohrady, Oddeleni Klinicke Hematologie
Prague, Srobarova, Czechia
- Fakultni Nemocnice Brno, Interni Hematoonkologicka Klinika
Brno, Czechia
- Fakultni Nemocnice Hradec Kralove, 2. Interni Klinika-Oddeleni Klinicke Hematologie
Hradec Králové, Czechia
- Chu Lille, Service Des Maladies Du Sang, Hopital Huriez
Lille, Lille Cedex, France
- Chu Angers, Service Des Maladies Du Sang
Angers, France
- Hopital Avicenne- Departement Onco-Hematologie
Bobigny, France
- Hopital Mignot
Le Chesnay, France
- Institut Paoli Calmettes
Marseille, France
- Chu Nantes Hotel Dieu, Service D'Hematologie Clinique
Nantes, France
- Chu de Bordeaux- Hopital Haut-Leveque, Centre Francois Magendle
Pessac, France
- Centre Hospitalier Lyon Sud - Service D'Hematologie - Pavillon Marcel Berard - Bat. 1g - 1er Etage, 165 Chemin Du Grand Revoyet
Pierre-Bénite, France
- Service D'Hematologie- Hopital Purpan- Chu de Toulouse
Toulouse, France
- St. Johannes-Hospital
Duisburg, Germany
- Klinikum Frankfurt Am Main-Hochst, Department of Hematology and Oncology, Klinikum Frankfurt Academic Hospital of the University of Frankfurt
Frankfurt, Germany
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 17 Dec 2010
- Primary completion
- 26 Sept 2014
- Completion
- 1 Mar 2017
- Last update posted
- 22 Aug 2018
- Registered enrollment
- 711
- Registry id
- NCT01191801
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.